These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 26478578)

  • 1. Diagnostic accuracy of CERAD total score in a Colombian cohort with mild cognitive impairment and Alzheimer's disease affected by E280A mutation on presenilin-1 gene.
    Aguirre-Acevedo DC; Jaimes-Barragán F; Henao E; Tirado V; Muñoz C; Reiman EM; Tariot PN; Langbaum JB; Lopera F
    Int Psychogeriatr; 2016 Mar; 28(3):503-10. PubMed ID: 26478578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study.
    Acosta-Baena N; Sepulveda-Falla D; Lopera-Gómez CM; Jaramillo-Elorza MC; Moreno S; Aguirre-Acevedo DC; Saldarriaga A; Lopera F
    Lancet Neurol; 2011 Mar; 10(3):213-20. PubMed ID: 21296022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CERAD test performances in amnestic mild cognitive impairment and Alzheimer's disease.
    Karrasch M; Sinervä E; Grönholm P; Rinne J; Laine M
    Acta Neurol Scand; 2005 Mar; 111(3):172-9. PubMed ID: 15691286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CERAD neuropsychological compound scores are accurate in detecting prodromal alzheimer's disease: a prospective AddNeuroMed study.
    Paajanen T; Hänninen T; Tunnard C; Hallikainen M; Mecocci P; Sobow T; Tsolaki M; Vellas B; Lovestone S; Soininen H
    J Alzheimers Dis; 2014; 39(3):679-90. PubMed ID: 24246420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.
    Ayutyanont N; Langbaum JB; Hendrix SB; Chen K; Fleisher AS; Friesenhahn M; Ward M; Aguirre C; Acosta-Baena N; Madrigal L; Muñoz C; Tirado V; Moreno S; Tariot PN; Lopera F; Reiman EM
    J Clin Psychiatry; 2014 Jun; 75(6):652-60. PubMed ID: 24816373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of Mild Cognitive Impairment Using the Thai Version of the Consortium to Establish a Registry for Alzheimer's Disease Tests: A Multivariate and Machine Learning Study.
    Tunvirachaisakul C; Supasitthumrong T; Tangwongchai S; Hemrunroj S; Chuchuen P; Tawankanjanachot I; Likitchareon Y; Phanthumchinda K; Sriswasdi S; Maes M
    Dement Geriatr Cogn Disord; 2018; 45(1-2):38-48. PubMed ID: 29617684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CERAD neuropsychological battery total score in multinational mild cognitive impairment and control populations: the AddNeuroMed study.
    Paajanen T; Hänninen T; Tunnard C; Mecocci P; Sobow T; Tsolaki M; Vellas B; Lovestone S; Soininen H; Addneuromed Consortium
    J Alzheimers Dis; 2010; 22(4):1089-97. PubMed ID: 20930314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CERAD neuropsychological assessment battery total score detects and predicts Alzheimer disease dementia with high diagnostic accuracy.
    Wolfsgruber S; Jessen F; Wiese B; Stein J; Bickel H; Mösch E; Weyerer S; Werle J; Pentzek M; Fuchs A; Köhler M; Bachmann C; Riedel-Heller SG; Scherer M; Maier W; Wagner M;
    Am J Geriatr Psychiatry; 2014 Oct; 22(10):1017-28. PubMed ID: 23759289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of digital clock drawing test in comparison with CERAD neuropsychological battery total score for discrimination of patients in the early course of Alzheimer's disease from healthy individuals.
    Müller S; Herde L; Preische O; Zeller A; Heymann P; Robens S; Elbing U; Laske C
    Sci Rep; 2019 Mar; 9(1):3543. PubMed ID: 30837580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Validation of the Hungarian version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild cognitive impairment].
    Papp E; Pákáski M; Drótos G; Kálmán J
    Psychiatr Hung; 2012; 27(6):426-34. PubMed ID: 23429337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic accuracy of the Phototest for cognitive impairment and dementia in Argentina.
    Russo MJ; Iturry M; Sraka MA; Bartoloni L; Carnero Pardo C; Allegri RF
    Clin Neuropsychol; 2014; 28(5):826-40. PubMed ID: 24970674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examining Sex Differences in Markers of Cognition and Neurodegeneration in Autosomal Dominant Alzheimer's Disease: Preliminary Findings from the Colombian Alzheimer's Prevention Initiative Biomarker Study.
    Vila-Castelar C; Guzmán-Vélez E; Pardilla-Delgado E; Buckley RF; Bocanegra Y; Baena A; Fox-Fuller JT; Tirado V; Muñoz C; Giraldo M; Acosta-Baena N; Rios-Romenets S; Langbaum JB; Tariot PN; Lopera F; Reiman EM; Quiroz YT
    J Alzheimers Dis; 2020; 77(4):1743-1753. PubMed ID: 32925067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive decline in patients with familial Alzheimer's disease associated with E280a presenilin-1 mutation: a longitudinal study.
    Rosselli MC; Ardila AC; Moreno SC; Standish VC; Arango-Lasprilla JC; Tirado VM; Ossa JM; Goate AM; Kosik KS; Lopera F
    J Clin Exp Neuropsychol; 2000 Aug; 22(4):483-95. PubMed ID: 10923058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study.
    Fleisher AS; Chen K; Quiroz YT; Jakimovich LJ; Gomez MG; Langois CM; Langbaum JB; Ayutyanont N; Roontiva A; Thiyyagura P; Lee W; Mo H; Lopez L; Moreno S; Acosta-Baena N; Giraldo M; Garcia G; Reiman RA; Huentelman MJ; Kosik KS; Tariot PN; Lopera F; Reiman EM
    Lancet Neurol; 2012 Dec; 11(12):1057-65. PubMed ID: 23137949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DemTect®--effective to asses MCI and dementia--validation study of the Polish language version.
    Wojtyńska R; Szcześniak D
    Aging Ment Health; 2016; 20(5):510-6. PubMed ID: 25811731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CERAD-neuropsychological battery in screening mild Alzheimer's disease.
    Sotaniemi M; Pulliainen V; Hokkanen L; Pirttilä T; Hallikainen I; Soininen H; Hänninen T
    Acta Neurol Scand; 2012 Jan; 125(1):16-23. PubMed ID: 21198445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study.
    Reiman EM; Quiroz YT; Fleisher AS; Chen K; Velez-Pardo C; Jimenez-Del-Rio M; Fagan AM; Shah AR; Alvarez S; Arbelaez A; Giraldo M; Acosta-Baena N; Sperling RA; Dickerson B; Stern CE; Tirado V; Munoz C; Reiman RA; Huentelman MJ; Alexander GE; Langbaum JB; Kosik KS; Tariot PN; Lopera F
    Lancet Neurol; 2012 Dec; 11(12):1048-56. PubMed ID: 23137948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can the CERAD neuropsychological battery be used to assess cognitive impairment in Parkinson's disease?
    Camargo CHF; Bronzini A; Tolentino ES; Medyk C; Schultz-Pereira GL
    Arq Neuropsiquiatr; 2018 Mar; 76(3):145-149. PubMed ID: 29809231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reliability and validity of A Quick Test of Cognitive Speed for detecting early-stage dementia in elderly Japanese.
    Takahashi F; Awata S; Sakuma N; Inagaki H; Ijuin M
    Psychogeriatrics; 2012 Jun; 12(2):75-82. PubMed ID: 22712639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical utility of naturalistic action test in differentiating mild cognitive impairment from early dementia in memory clinic.
    Bruce I; Ntlholang O; Crosby L; Cunningham C; Lawlor B
    Int J Geriatr Psychiatry; 2016 Mar; 31(3):309-15. PubMed ID: 26264127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.